eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2007
vol. 11
 
Share:
Send email
Share:
abstract:

The influence of disease chemosensitivity and residual tumour mass on the results of autologous haematopoietic cell transplantation (AHCT) in Hodgkin’s lymphoma (HL) – single centre experience in 173 patients

Beata Stella-Hołowiecka
,
Tomasz Czerw
,
Aleksandra Hołowiecka-Goral
,
Lucja Kachel
,
Maria Wojciechowska
,
Sebastian Giebel
,
Grzegorz Helbig
,
Jerzy Wojnar
,
Małgorzata Krawczyk-Kuliś
,
Jerzy Hołowiecki

Współczesna Onkologia (2007) vol. 11; 4 (175-180)
Online publish date: 2007/06/19
View full text Get citation
 
Introduction: High dose chemotherapy followed by autologous haematopoietic cell transplantation (AHCT) is widely used in refractory and relapsed Hodgkin’s lymphoma (HL). AHCT is also offered for patients with high risk disease. Objective: We retrospectively evaluated the results of AHCT in 173 HL patients performed in a single institution.
Material and methods: Characteristics of patients: 40 patients in second or subsequent CR (CR>2), 52 in first partial remission (PR=1), 35 in PR>2, 29 patients with primary resistance (NR) or with resistance at relapse (RR). A subgroup of 17 high risk HL patients received AHCT as consolidation in CR1. Results: The 100-day mortality rate was 2.9%. The 7-year overall survival (OS) and progression-free survival (PFS) rates for the entire analysed group were 72 and 56% respectively and the rates did not differ significantly between patients transplanted in CR>1 and PR>1. Increased lactate dehydrogenase (LDH) activity was found to be a predictive factor for relapse incidence (Rl) in both groups; p<0.04. The 7-year OS and PFS rates were significantly higher in patients transplanted in CR and PR compared to NR patients (76vs54%; p=0.0002) and to RR patients (61vs35%; p=0.0018).
Conclusions: AHCT is a safe and effective treatment strategy, especially in patients with at least partially chemosensitive disease, in patients with CR1/PR1 after front line treatment and in those who achieved CR>2 or PR>2 after relapse. The results of AHCT in NR or RR patients are unsatisfactory and these patients should be considered for allogeneic transplantation or for other salvage strategies within clinical trials.
keywords:

Hodgkin’s lymphoma – autologous haematopoietic cell transplantation – results
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.